Published 3 days ago • loading... • Updated 2 days ago

Breakthrough Clinical Trial: OKYO's New Eye Drug Shows 80% Pain Relief for Untreatable Corneal Condition

New eye treatment achieves 80% pain reduction in Phase 2 trial for untreatable corneal condition. Fast-tracked therapy shows promise for NCP patients. See full data.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

Clinical Trials Arena

OKYO reports top-line data from neuropathic corneal pain therapy trial

OKYO Pharma has reported encouraging top-line outcomes from the randomised Phase II trial of urcosimod to treat NCP.The post OKYO reports top-line data from neuropathic corneal pain therapy trial appeared first on Clinical Trials Arena.

2 days ago

Read Full Article

stocktitan.net

Breakthrough Clinical Trial: OKYO's New Eye Drug Shows 80% Pain Relief for Untreatable Corneal Condition

New eye treatment achieves 80% pain reduction in Phase 2 trial for untreatable corneal condition. Fast-tracked therapy shows promise for NCP patients. See full data.

3 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right